Evidence map›Paper›PMID 35909208›Full record

ReviewMolecular and cellular biochemistry2023

Genetic advancements in obesity management and CRISPR-Cas9-based gene editing system.

Muthukumaran Jayachandran, Zhaoliang Fei, Shen Qu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular and cellular biochemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. A narrative review of approved and emerging anti-obesity medications.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Muthukumaran JayachandranDepartment of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China.
Zhaoliang FeiDepartment of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China. feiz@sibcb.ac.cn.ORCID http://orcid.org/0000-0002-5400-8126
Shen QuDepartment of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China. qushencn@hotmail.com.ORCID http://orcid.org/0000-0003-0811-7070

Funding

National Natural Science Foundation of China 81970677Shanghai Committee of Science and Technology, China 17DZ1910603Shanghai Committee of Science and Technology, China 18411951803Shanghai Committee of Science and Technology, China 19DZ1910200The Fundamental Research Funds for the Central Universities of Tongji University 22120190210The National Key R&D Program of China 2016YFC1305600The National Key R&D Program of China 2018YFC1314101
6 · The paper itself

Abstract

Human genome research has reached new heights in the recent decade thanks to a major advance in genome editing. Genome editing enables scientists to understand better the functions of a single gene and its impact on a wide range of diseases. In brief, genome editing is a technique for introducing alterations into specific DNA sequences, such as insertions, deletions, or base substitutions. Several methods are adopted to perform genome editing and clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated nuclease 9 (Cas9) systems. Unfortunately, despite substantial progress in understanding the molecular pathways behind obesity, anti-obesity medications are now ineffective. If you are obese, a 10% weight decrease would be preferable to healthy body weight for most people. CRISPR-Cas9, on the other hand, has been shown to reduce body weight by an astonishing 20%. Hence, this updated review elaborates on the molecular basis of obesity, risk factors, types of gene therapy, possible mechanisms, and advantages of the CRISPR-Cas9 system over other methods.

Indexed as

Gene EditingObesity ManagementBody WeightCRISPR-Cas SystemsGenetic TherapyHumansBasal metabolic indexClustered regularly interspaced short palindromic repeats interferenceFatty acid-binding protein-4Gene editingObesity

Identifiers

PMID35909208

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.